Holen Sie sich die Stockscreener-App
7.20
17.33%
1.14
Handel nachbörslich:
7.20
Schlusskurs vom Vortag:
$6.06
Offen:
$5.9201
24-Stunden-Volumen:
1.44M
Relative Volume:
15.15
Marktkapitalisierung:
$120.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.88M
KGV:
-7.3469
EPS:
-0.98
Netto-Cashflow:
$-10.29M
1W Leistung:
+11.27%
1M Leistung:
+17.52%
6M Leistung:
+30.46%
1J Leistung:
-9.31%
1-Tages-Spanne:
$5.83
$7.75
1-Wochen-Bereich:
$5.83
$7.75
52-Wochen-Spanne:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
Firmenname
Coya Therapeutics Inc
Sektor
Branche
Telefon
650.739.3939
Adresse
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Vergleichen Sie COYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
7.20 | 101.35M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Lake Street | Buy |
| 2024-12-04 | Eingeleitet | D. Boral Capital | Buy |
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
Coya Therapeutics jumps as Greenlight discusses in Q3 letter - Seeking Alpha
Best data tools to analyze Coya Therapeutics Inc. stockWeekly Profit Summary & Weekly Top Performers Watchlists - newser.com
Price momentum metrics for Coya Therapeutics Inc. explainedJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
News impact scoring models applied to Coya Therapeutics Inc.2025 Investor Takeaways & Daily Price Action Insights - newser.com
Will Coya Therapeutics Inc. stock go up soonQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Will Coya Therapeutics Inc. stock deliver better than expected guidanceEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Published on: 2025-10-13 10:06:24 - newser.com
When is the best time to exit Coya Therapeutics Inc.Trade Signal Summary & Expert Approved Momentum Ideas - newser.com
Should you hold or exit Coya Therapeutics Inc. nowQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Reversal indicators forming on Coya Therapeutics Inc. stockLong Setup & AI Enhanced Market Trend Forecasts - newser.com
Is Coya Therapeutics Inc. stock poised for growthTrade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Is now a turning point for Coya Therapeutics Inc.Portfolio Return Summary & Precise Buy Zone Tips - newser.com
What data driven models say about Coya Therapeutics Inc.’s futureBreakout Watch & Daily Chart Pattern Signal Reports - newser.com
Candlestick signals on Coya Therapeutics Inc. stock todayQuarterly Profit Review & Safe Entry Trade Reports - newser.com
Quantitative breakdown of Coya Therapeutics Inc. recent move2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
What momentum shifts mean for Coya Therapeutics Inc.Quarterly Investment Review & Low Volatility Stock Suggestions - newser.com
Coya Therapeutics (NASDAQ:COYA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-09 03:57:14 - newser.com
Ranking Coya Therapeutics Inc. among high performing stocks via tools2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - BioSpace
What analysts say about Coya Therapeutics Inc stockPrice Momentum Alerts & Budget Friendly Portfolio Growth - earlytimes.in
Predicting Coya Therapeutics Inc. trend using moving averages2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
What sentiment indicators say about Coya Therapeutics Inc. stockWeekly Risk Report & Community Consensus Picks - newser.com
How to integrate Coya Therapeutics Inc. into portfolio analysis toolsWeekly Trading Summary & Stock Portfolio Risk Management - newser.com
Will Coya Therapeutics Inc. stock outperform value stocksPrice Action & Risk Controlled Daily Trade Plans - newser.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.20 Consensus PT from Analysts - Defense World
What drives Coya Therapeutics Inc stock priceDividend Yield Trends & Trusted Financial Advisors at No Cost - earlytimes.in
BTIG Reiterates Buy Rating on COYA with $15 Price Target | COYA Stock News - GuruFocus
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from BTIG Research - MarketBeat
Positive Outlook for Coya Therapeutics Driven by Promising COYA-302 Clinical Developments and Regulatory Support - TipRanks
Coya completes FTD combination therapy trial enrolment - Yahoo Finance
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - Quantisnow
COYA Stock Analyst Rating: D. Boral Capital Maintains "Buy" Rati - GuruFocus
Coya Therapeutics' (COYA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Finanzdaten der Coya Therapeutics Inc-Aktie (COYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Coya Therapeutics Inc-Aktie (COYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SNYDER DAVID S | Chief Financial Officer |
Nov 14 '24 |
Buy |
7.19 |
1,800 |
12,934 |
8,800 |
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):